Shao et al. demonstrated that CPA4 overexpression promotes the progression of aggressive clinical stage in pancreatic cancer and that the downregulation of CPA4 inhibits non-small-cell lung cancer growth [15,18]. Here, CPA4 is linked to pancreatic neoplasm.